Immunovant (IMVT) Assets (2018 - 2026)

Immunovant (IMVT) has 9 years of Assets data on file, last reported at $957.0 million in Q1 2026.

• Quarterly Assets rose 23.29% year-over-year to $957.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $957.0 million (up 23.29% YoY) and the FY2026 annual result came in at $957.0 million, up 23.29% from the prior year.
• Assets eased to $957.0 million in Q1 2026, from $1.1 billion in the prior quarter.
• In the past five years, Assets ranged from a high of $1.1 billion in Q4 2025 to a low of $292.1 million in Q3 2023.
• A 5-year average of $578.9 million and a median of $515.7 million in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2024 — Assets tumbled 40.83% — and 2025, when it soared 150.01%.
• Tracing IMVT's Assets over 5 years: stood at $456.2 million in 2022, then soared by 55.94% to $711.4 million in 2023, then plunged by 40.83% to $420.9 million in 2024, then soared by 150.01% to $1.1 billion in 2025, then declined by 9.06% to $957.0 million in 2026.
• The last three Assets figures came in at $957.0 million (Q1 2026), $1.1 billion (Q4 2025), and $583.0 million (Q3 2025), per Business Quant data.